RTS,S/AS01B

BIOLOGICAL2 trials

Sponsors

University of Oxford, GlaxoSmithKline

Conditions

MalariaPlasmodium Falciparum Malaria

Phase 1

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

CompletedNCT01883609

University of OxfordPlasmodium Falciparum Malaria

Start: 2013-09-30End: 2014-08-31Updated: 2014-10-01

Phase 2

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

CompletedNCT03162614

GlaxoSmithKlineMalaria

Start: 2017-05-24End: 2018-09-24Updated: 2020-10-27

Related Papers

Identification of RTS,S/AS01 vaccine–induced humoral biomarkers predictive of protection against controlled human malaria infection

JCI Insight2024-10-075 citations

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults

The Journal of Infectious Diseases2020-07-1744 citations

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01<sub>B</sub>With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

The Journal of Infectious Diseases2016-06-1594 citations